ArticleInfection and drug resistance2025
Identification of Specific LncRNA Markers in Severe Tuberculosis for Early Diagnosis.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and validation of a primary care-accessible risk prediction model for severe pulmonary TB.IJTLD open · 2026Article
- The role of long non-coding RNA HCP5 in ulcerative cutaneous tuberculosis therapy introduction.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The progression of tuberculosis to severe disease is the main cause of death of tuberculosis patients. Early identification of severe tuberculosis is very important. LncRNA can be used as a potential marker in the diagnosis of tuberculosis, but there is a lack of research on lncRNA in the field of severe tuberculosis. Methods: Peripheral blood samples of severe pulmonary tuberculosis patients, mild pulmonary tuberculosis patients and healthy controls were collected to extract peripheral blood monocytes. The RNA was then extracted and sent to the SBC human ceRNA V1.0 analysis. The results were verified by qPCR and analyzed by KEGG and GO analyses. Differentially expressed lncRNAs were measured by ROC curves. Results: Four lncRNAs exhibited statistically distinct expression patterns in STB versus MTB groups (NR_033909: p=0.0097; lnc-MYCBPAP-2:4: p=0.0053; lnc-PRDM7-1:2: p<0.0001; NR_033841: p=0.0279). The areas under the curve (AUC) value are respectively 0.7280(lnc-PRDM7-1:2), 0.7288(lnc-MYCBPAP-2:4), 0.6647(NR_033909) and 0.6615(NR_033841). Conclusion: LncRNAs NR_033909, lnc-MYCBPAP-2:4, lnc-PRDM7-1:2 and NR_033841 may demonstrate diagnostic potential for differentiating severe from mild pulmonary tuberculosis cases. These results create a platform for monitoring TB progression and open new avenues for studying disease pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.